Oncogene Proteins, Fusion
"Oncogene Proteins, Fusion" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
The GENETIC TRANSLATION products of the fusion between an ONCOGENE and another gene. The latter may be of viral or cellular origin.
| Descriptor ID |
D015514
|
| MeSH Number(s) |
D12.776.602.500.500 D12.776.624.664.500
|
| Concept/Terms |
Oncogene Proteins, Fusion- Oncogene Proteins, Fusion
- Fusion Oncogene Proteins
- Proteins, Fusion Oncogene
- Oncogene Proteins, Chimeric
- Fusion Proteins, Oncogene
- Oncogene Fusion Proteins
- Proteins, Oncogene Fusion
- Chimeric Oncogene Proteins
- Proteins, Chimeric Oncogene
- Chimeric Proteins, Oncogene
- Oncogene Chimeric Proteins
- Proteins, Oncogene Chimeric
|
Below are MeSH descriptors whose meaning is more general than "Oncogene Proteins, Fusion".
Below are MeSH descriptors whose meaning is more specific than "Oncogene Proteins, Fusion".
This graph shows the total number of publications written about "Oncogene Proteins, Fusion" by people in this website by year, and whether "Oncogene Proteins, Fusion" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2003 | 0 | 1 | 1 |
| 2019 | 1 | 0 | 1 |
| 2020 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Oncogene Proteins, Fusion" by people in Profiles.
-
Core-binding factor acute myeloid leukemia with inv(16): Older age and high white blood cell count are risk factors for treatment failure. Int J Lab Hematol. 2021 02; 43(1):e19-e25.
-
Cryptic partial insertion of the RARA gene into the PML gene without reciprocal RARA-PML fusion: a case report and review of literature. Acta Oncol. 2020 Dec; 59(12):1496-1499.
-
COMMD3:BMI1 Fusion and COMMD3 Protein Regulate C-MYC Transcription: Novel Therapeutic Target for Metastatic Prostate Cancer. Mol Cancer Ther. 2019 11; 18(11):2111-2123.
-
Gene copy mapping of the ERBB2/TOP2A region in breast cancer. Genes Chromosomes Cancer. 2004 May; 40(1):19-31.
-
High prevalence of BRAF gene mutation in papillary thyroid carcinomas and thyroid tumor cell lines. Cancer Res. 2003 Aug 01; 63(15):4561-7.